IDEAYA Biosciences — Third Quarter 2026 Earnings Summary

IDEAYA Biosciences submitted a New Drug Application to the FDA in the third quarter of 2026 for darovasertib combined with crizotinib to treat metastatic uveal melanoma. The company presented clinical data at ESMO 2026 demonstrating the therapy's efficacy across different patient populations and lines of therapy, while also announcing the closure of the Phase 3 OptimUM-010 trial to reallocate resources toward other pipeline programs. Financially, the company reported $1.15 billion in cash and cash equivalents as of September 30, 2026, with a net loss of $125.7 million for the quarter. Additionally, IDEAYA highlighted progress on its antibody-drug conjugate IDE849 in small cell lung cancer and plans to initiate Phase 3 trials for this asset by the end of the year.